Compare Stocks: PRFX, REVB, XRTX, and RDHL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRFX PainReform	$0.89 +1.0%	$0.99	$0.85 ▼ $7.95	$770K	1.08	373,857 shs	35,616 shs
RDHL Redhill Biopharma	$0.48 -1.8%	$0.61	$0.46 ▼ $2.14	$3M	4.91	190,315 shs	57,869 shs
REVB Revelation Biosciences	$0.75 -3.2%	$1.00	$0.75 ▼ $6.76	$3.10M	-0.07	33,853 shs	34,725 shs
XRTX XORTX Therapeutics	$1.73 +1.8%	$2.04	$1.59 ▼ $7.05	$3.09M	0.78	693,736 shs	40,737 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRFX PainReform	-3.88%	-8.99%	-8.65%	-34.01%	-87.18%
RDHL Redhill Biopharma	-1.44%	-2.51%	-31.97%	-33.03%	-74.06%
REVB Revelation Biosciences	+1.77%	-9.57%	-22.91%	-21.51%	-87.05%
XRTX XORTX Therapeutics	-0.83%	-0.58%	-26.41%	-16.67%	-57.50%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
PRFX PainReform	$0.89 +1.0%	$0.99	$0.85 ▼ $7.95	$770K	1.08	373,857 shs	35,616 shs
RDHL Redhill Biopharma	$0.48 -1.8%	$0.61	$0.46 ▼ $2.14	$3M	4.91	190,315 shs	57,869 shs
REVB Revelation Biosciences	$0.75 -3.2%	$1.00	$0.75 ▼ $6.76	$3.10M	-0.07	33,853 shs	34,725 shs
XRTX XORTX Therapeutics	$1.73 +1.8%	$2.04	$1.59 ▼ $7.05	$3.09M	0.78	693,736 shs	40,737 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
PRFX PainReform	-3.88%	-8.99%	-8.65%	-34.01%	-87.18%
RDHL Redhill Biopharma	-1.44%	-2.51%	-31.97%	-33.03%	-74.06%
REVB Revelation Biosciences	+1.77%	-9.57%	-22.91%	-21.51%	-87.05%
XRTX XORTX Therapeutics	-0.83%	-0.58%	-26.41%	-16.67%	-57.50%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
PRFX PainReform	1.00	Sell	N/A	N/A
RDHL Redhill Biopharma	1.00	Sell	N/A	N/A
REVB Revelation Biosciences	1.00	Sell	N/A	N/A
XRTX XORTX Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest PRFX, REVB, XRTX, and RDHL Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/29/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
9/21/2026	XRTX XORTX Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/25/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/11/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/3/2026	RDHL Redhill Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/28/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	PRFX PainReform	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/9/2026	REVB Revelation Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
PRFX PainReform	$20K	38.85	N/A	N/A	$23.07 per share	0.04
RDHL Redhill Biopharma	$290K	10.15	N/A	N/A	$0.83 per share	0.58
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	$1.28 per share	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	$1.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
PRFX PainReform	-$5.02M	-$736.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	-$430K	$900.00	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	-$8.91M	-$12.31	N/A	N/A	N/A	N/A	-100.19%	-82.72%	11/5/2026 (Estimated)
XRTX XORTX Therapeutics	-$2.66M	-$2.73	N/A	N/A	N/A	N/A	-137.85%	-108.16%	11/12/2026 (Estimated)

Latest PRFX, REVB, XRTX, and RDHL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/3/2026	Q2 2026	PRFX PainReform	N/A	-$1.13	N/A	-$1.1250	N/A	$0.01 million
8/15/2026	Q2 2026	XRTX XORTX Therapeutics	N/A	-$1.05	N/A	-$1.05	N/A	N/A
8/6/2026	Q2 2026	REVB Revelation Biosciences	-$0.8750	-$0.87	+$0.0050	-$0.87	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
PRFX PainReform	N/A	N/A	N/A	N/A	N/A
RDHL Redhill Biopharma	N/A	N/A	N/A	N/A	N/A
REVB Revelation Biosciences	N/A	N/A	N/A	N/A	N/A
XRTX XORTX Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
PRFX PainReform	N/A	5.07	N/A
RDHL Redhill Biopharma	N/A	0.34	N/A
REVB Revelation Biosciences	N/A	6.22	6.22
XRTX XORTX Therapeutics	N/A	3.58	3.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
PRFX PainReform	37.28%
RDHL Redhill Biopharma	7.20%
REVB Revelation Biosciences	12.80%
XRTX XORTX Therapeutics	0.23%

Insider Ownership

Company	Insider Ownership
PRFX PainReform	34.40%
RDHL Redhill Biopharma	6.81%
REVB Revelation Biosciences	4.80%
XRTX XORTX Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
PRFX PainReform	7	870,000	570,000	Not Optionable
RDHL Redhill Biopharma	210	6.08 million	5.67 million	No Data
REVB Revelation Biosciences	9	3.98 million	3.79 million	Not Optionable
XRTX XORTX Therapeutics	N/A	1.82 million	1.69 million	Not Optionable

PRFX, REVB, XRTX, and RDHL Headlines

Recent News About These Companies

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO(TM), Targeting USD$700M+ U.S. Gout Market Opportunity

September 19, 2026 | barrons.com

XORTX Therapeutics Shares Rise 12% On IND Submission Plan

September 19, 2026 | rttnews.com

XORT Targets FDA IND Filing For XRx-026 Gout Program; NDA Submission Planned Within A Year

September 18, 2026 | rttnews.com

XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

September 18, 2026 | globenewswire.com

XORTX Begins Clinical, Commercial Manufacturing Of XORLO For Gout Program; Shares Surge To 31%

September 11, 2026 | rttnews.com

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | financialpost.comF

XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

September 10, 2026 | globenewswire.com

XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

September 8, 2026 | tipranks.com

XORTX Re-Engages Investor Relations Program

September 8, 2026 | financialpost.comF

XORTX Re-Engages Investor Relations Program

September 8, 2026 | globenewswire.com

XORTX Slips 10% As Investor Relations Program Is Terminated And Postponed

August 28, 2026 | rttnews.com

XORTX Announces Termination and Postponement of Investor Relations Program

August 28, 2026 | globenewswire.com

XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet

August 17, 2026 | tipranks.com

XORTX Therapeutics Inc.

August 11, 2026 | barrons.com

XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo

August 4, 2026 | tipranks.com

XORTX Therapeutics Inc. annonce la démission d'Anthony Giovinazzo de son poste d'administrateur

August 2, 2026 | zonebourse.comZ

XORTX Therapeutics Inc.: XORTX Announces Director Resignation

August 1, 2026 | finanznachrichten.de

XORTX Announces Director Resignation

July 31, 2026 | financialpost.comF

XORTX Announces Director Resignation

July 31, 2026 | globenewswire.com

XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight

July 29, 2026 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, REVB, XRTX, and RDHL Company Descriptions

PainReform NASDAQ:PRFX

$0.89 +0.01 (+0.98%)

Closing price 03:59 PM Eastern

Extended Trading

$0.91 +0.02 (+2.35%)

As of 06:18 PM Eastern

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and second trial for pain treatment of hernia repair operations. The company was incorporated in 2007 and is based in Tel Aviv, Israel.

Redhill Biopharma NASDAQ:RDHL

$0.48 -0.01 (-1.79%)

Closing price 04:00 PM Eastern

Extended Trading

$0.49 +0.00 (+0.41%)

As of 07:56 PM Eastern

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Revelation Biosciences NASDAQ:REVB

$0.75 -0.02 (-3.20%)

Closing price 03:59 PM Eastern

Extended Trading

$0.75 0.00 (-0.03%)

As of 07:54 PM Eastern

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was founded in 2020 and is based in San Diego, California.

XORTX Therapeutics NASDAQ:XRTX

$1.73 +0.03 (+1.76%)

Closing price 04:00 PM Eastern

Extended Trading

$1.76 +0.03 (+2.02%)

As of 07:59 PM Eastern

Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers. Its product and solution portfolio for the enterprise data storage industry includes storage enclosures, integrated application platforms and high performance computing (HPC) data storage solutions. In April 2014, Seagate Technology PLC completed the acquisition of Xyratex Ltd.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRFX, REVB, XRTX, and RDHL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRFX, REVB, XRTX, and RDHL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRFX, REVB, XRTX, and RDHL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, REVB, XRTX, and RDHL Company Descriptions

PainReform NASDAQ:PRFX

Redhill Biopharma NASDAQ:RDHL

Revelation Biosciences NASDAQ:REVB

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRFX, REVB, XRTX, and RDHL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRFX, REVB, XRTX, and RDHL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRFX, REVB, XRTX, and RDHL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRFX, REVB, XRTX, and RDHL Company Descriptions

PainReform NASDAQ:PRFX

Redhill Biopharma NASDAQ:RDHL

Revelation Biosciences NASDAQ:REVB

XORTX Therapeutics NASDAQ:XRTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools